Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven L Flamm

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Advances in Therapy|April 13, 2020
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C InfectionSteven L Flamm, Jens Kort, Steven E Marx, et al.
Advances in Therapy|July 29, 2022
Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing SurveillanceSteven L Flamm, Markus Peck-Radosavljevic, Takahiro Fukuhara, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 26, 2011
Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experienceAoife N Keeling, James D Flaherty, Amir H Davarpanah, et al.
Hepatology (Baltimore, Md.)|August 18, 2016
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort studyElliot B Tapper, Bruce R Bacon, Michael P Curry, et al.
The American Journal of Cardiology|January 26, 2002
Predictive value of stress myocardial perfusion imaging in liver transplant candidatesCharles J Davidson, Mihai Gheorghiade, James D Flaherty, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Advances in Therapy|April 13, 2020
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C InfectionSteven L Flamm, Jens Kort, Steven E Marx, et al.
Advances in Therapy|July 29, 2022
Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing SurveillanceSteven L Flamm, Markus Peck-Radosavljevic, Takahiro Fukuhara, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 26, 2011
Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experienceAoife N Keeling, James D Flaherty, Amir H Davarpanah, et al.
Hepatology (Baltimore, Md.)|August 18, 2016
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort studyElliot B Tapper, Bruce R Bacon, Michael P Curry, et al.
The American Journal of Cardiology|January 26, 2002
Predictive value of stress myocardial perfusion imaging in liver transplant candidatesCharles J Davidson, Mihai Gheorghiade, James D Flaherty, et al.
Journal of Clinical Gastroenterology|May 16, 2014
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicitySteven L Flamm, Andrew J Muir, Michael W Fried, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Pageof 7